| 000 | 01751 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515090423.0 | ||
| 264 | 0 | _c20071128 | |
| 008 | 200711s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1038/sj.clpt.6100362 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Y | |
| 245 | 0 | 0 |
_aAdvances in the treatment of tuberculosis. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cNov 2007 |
||
| 300 |
_a595-600 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xdrug therapy |
| 650 | 0 | 4 |
_aAdamantane _xanalogs & derivatives |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xpharmacology |
| 650 | 0 | 4 |
_aAntitubercular Agents _xpharmacology |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Resistance, Bacterial |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aDrugs, Investigational _xpharmacology |
| 650 | 0 | 4 |
_aEthylenediamines _xpharmacology |
| 650 | 0 | 4 |
_aExtensively Drug-Resistant Tuberculosis _xdrug therapy |
| 650 | 0 | 4 |
_aFluoroquinolones _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoniazid _xtherapeutic use |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 |
_aNitroimidazoles _xpharmacology |
| 650 | 0 | 4 |
_aOxazoles _xpharmacology |
| 650 | 0 | 4 |
_aPyrazinamide _xtherapeutic use |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Refusal |
| 650 | 0 | 4 |
_aTuberculosis, Multidrug-Resistant _xdrug therapy |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xdrug therapy |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 82 _gno. 5 _gp. 595-600 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.clpt.6100362 _zAvailable from publisher's website |
| 999 |
_c17421069 _d17421069 |
||